TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003–15 6
Financial performance, 2003–15 7
Merck KGaA: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 15
Chapter 3 Quarterly news update 23
Latest quarterly sales 23
Latest comment 23
Latest prescription pharma product news 24
Latest corporate news 29
Future product milestones 31
Chapter 4 Company introduction 32
Key findings 32
Background 33
Key corporate developments 33
M&A history 33
Current corporate structure 34
Chapter 5 Company sales 36
Key findings 36
Prescription pharmaceutical sales and growth rate analysis, 2003–15 37
Product analysis 38
Therapy area analysis 44
Geographic analysis 46
Launch/core/expiry analysis 48
Molecule type analysis 53
Externalization analysis 55
Chapter 6 Company financials 57
Key findings 57
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09 58
Operating costs and profit analysis 59
Chapter 7 Appendix 64
Abbreviations 64
Exchange rates 65
About Datamonitor 66
Datamonitor consulting 66
Disclaimer 68
TABLE OF TABLES
Table 1: Merck KGaA – PharmaVitae forecasts at a glance 8
Table 2: Merck KGaA quarterly sales ($m), Q209–Q210 23
Table 3: Merck KGaA future product milestones, 2010–12 31
Table 4: Merck KGaA product portfolio overview ($m), 2003–09 40
Table 5: Merck KGaA product portfolio overview ($m), 2009–15 42
Table 6: Merck KGaA prescription pharmaceutical sales by therapy area ($m), 2009–15 45
Table 7: Merck KGaA prescription pharmaceutical sales by geographic region ($m), 2009–15 47
Table 8: Merck KGaA launch portfolio overview ($m), 2009–15 49
Table 9: Merck KGaA core portfolio overview ($m), 2009–15 50
Table 10: Merck KGaA expiry portfolio overview ($m), 2009–15 51
Table 11: Merck KGaA prescription pharmaceutical sales by molecule type ($m), 2009–15 54
Table 12: Merck KGaA prescription pharmaceutical sales by source ($m), 2009–15 56
Table 13: Total Merck KGaA sales by business unit ($m), 2002–08 58
Table 14: Merck KGaA operating revenue/cost analysis ($m), 2003–09 60
Table 15: Merck KGaA operating cost ratio analysis (% of total revenues), 2003–09 61
Table 16: Merck KGaA operating cost ratio analysis (% of total revenues), 2009–15 62
Table 17: Merck KGaA operating revenue/cost analysis ($m), 2009–15 63
Table 18: Exchange rates, 2010 65
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 6
Figure 3: Merck KGaA’s financial performance ($m), 2003–15 7
Figure 4: Merck KGaA’s biologics focus (percentage of branded ethical sales), 2001, 2006 and 2007 10
Figure 5: Merck KGaA’s therapeutic focus (percentage of branded ethical sales), 2001, 2006 and 2007 11
Figure 6: Merck KGaA’s restructuring and its effects on operating margins, 2001–08 13
Figure 7: Merck KGaA SWOT analysis 15
Figure 8: Current corporate structure 34
Figure 9: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 37
Figure 10: Merck KGaA Key product sales ($m), 2003–15 38
Figure 11: Merck KGaA key sales growth drivers and resistors ($m), 2003–09 41
Figure 12: Merck KGaA key sales growth drivers and resistors ($m), 2009–15 43
Figure 13: Merck KGaA prescription pharmaceutical sales by therapy area ($m), 2003–15 44
Figure 14: Merck KGaA prescription pharmaceutical sales by geographic region ($m), 2003–15 46
Figure 15: Merck KGaA launch/core/expiry configuration ($m), 2009–15 52
Figure 16: Merck KGaA prescription pharmaceutical sales by molecule type ($m), 2003–15 53
Figure 17: Merck KGaA prescription pharmaceutical sales by source ($m), 2003-15 55
Figure 18: Merck KGaA operating revenue/cost analysis ($m), 2003–15 59
[Inhaltsverzeichnis ausblenden]
